163 related articles for article (PubMed ID: 10328761)
1. A reconstituted dilute blood clot lysis assay for the medium throughput screening of thrombolytic compounds.
Gadbut AP; Schullek JR; Hanel AM; MacAllan DR
Anal Biochem; 1999 May; 270(1):24-32. PubMed ID: 10328761
[TBL] [Abstract][Full Text] [Related]
2. Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA).
Trusen B; Ries M; Zenker M; Rauh M; Beinder E; Keuper H; Harms D
Semin Thromb Hemost; 1998; 24(6):599-604. PubMed ID: 10066156
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of concomitant thrombin-mediated fibrin formation enhances clot lysis in whole blood.
Haskel EJ; Eisenberg PR; Abendschein DR
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):7-13. PubMed ID: 8457655
[TBL] [Abstract][Full Text] [Related]
4. Human thrombin and calcium bound factor Xa significantly shorten tPA-induced fibrin clot lysis time via neutralization of plasminogen activator inhibitor type 1 activity.
Urano T; Nagai N; Matsuura M; Ihara H; Takada Y; Takada A
Thromb Haemost; 1998 Jul; 80(1):161-6. PubMed ID: 9684803
[TBL] [Abstract][Full Text] [Related]
5. Inhibitor-resistant tissue-type plasminogen activator: an improved thrombolytic agent in vitro.
Shohet RV; Spitzer S; Madison EL; Bassel-Duby R; Gething MJ; Sambrook JF
Thromb Haemost; 1994 Jan; 71(1):124-8. PubMed ID: 8165630
[TBL] [Abstract][Full Text] [Related]
6. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
7. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
[TBL] [Abstract][Full Text] [Related]
8. Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis.
van Giezen JJ; Boon GI; Jansen JW; Bouma BN
Thromb Haemost; 1993 Apr; 69(4):381-6. PubMed ID: 8497851
[TBL] [Abstract][Full Text] [Related]
9. A multiparameter test of clot formation and fibrinolysis for in-vitro drug screening.
Kostka B; Para J; Sikora J
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):611-8. PubMed ID: 17890947
[TBL] [Abstract][Full Text] [Related]
10. Cross-species pharmacologic evaluation of plasmin as a direct-acting thrombolytic agent: ex vivo evaluation for large animal model development.
Landskroner K; Olson N; Jesmok G
J Vasc Interv Radiol; 2005 Mar; 16(3):369-77. PubMed ID: 15758133
[TBL] [Abstract][Full Text] [Related]
11. In vitro studies on the fibrinolytic, thrombolytic and fibrinogenolytic properties of a tissue plasminogen activator from guinea pig keratocytes.
Electricwala A; Ling RJ; Sutton PM; Griffiths B; Riley PA; Atkinson T
Thromb Haemost; 1985 Apr; 53(2):200-3. PubMed ID: 4040659
[TBL] [Abstract][Full Text] [Related]
12. Qualitative description of factors involved in the retraction and lysis of dilute whole blood clots and in the aggregation and retraction of platelets.
Taylor FB; Müller-Eberhard HJ
J Clin Invest; 1970 Nov; 49(11):2068-85. PubMed ID: 4248913
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a small molecule PAI-1 inhibitor, ZK4044.
Liang A; Wu F; Tran K; Jones SW; Deng G; Ye B; Zhao Z; Snider RM; Dole WP; Morser J; Wu Q
Thromb Res; 2005; 115(4):341-50. PubMed ID: 15668194
[TBL] [Abstract][Full Text] [Related]
14. Turbulent axially directed flow of plasma containing rt-PA promotes thrombolysis of non-occlusive whole blood clots in vitro.
Tratar G; Blinc A; Strukelj M; Mikac U; Sersa I
Thromb Haemost; 2004 Mar; 91(3):487-96. PubMed ID: 14983224
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen, plasminogen activator, and platelets in the regulation of clot lysis. Reconstitution and patient studies.
Carroll RC; Radcliffe RD; Taylor FB; Gerrard JM
J Lab Clin Med; 1982 Dec; 100(6):986-96. PubMed ID: 6890569
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic effects due to pharmacological modulation of thrombin-activatable fibrinolysis inhibitor in rats.
Soni H; Sharma A; Bhatt S; Jain MR; Patel PR
Pharmacology; 2008; 82(4):304-9. PubMed ID: 18936552
[TBL] [Abstract][Full Text] [Related]
17. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis.
Parise P; Morini M; Agnelli G; Ascani A; Nenci GG
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):721-7. PubMed ID: 8292721
[TBL] [Abstract][Full Text] [Related]
18. Resistance of porcine blood clots to lysis relates to poor activation of porcine plasminogen by tissue plasminogen activator.
Flight SM; Masci PP; Lavin MF; Gaffney PJ
Blood Coagul Fibrinolysis; 2006 Jul; 17(5):417-20. PubMed ID: 16788320
[TBL] [Abstract][Full Text] [Related]
19. Effect of non-heparin thrombin antagonists on thrombin generation, platelet function, and clot structure in whole blood.
Carr ME; Angchaisuksiri P; Carr SL; Martin EJ
Cell Biochem Biophys; 2003; 39(2):89-99. PubMed ID: 14515016
[TBL] [Abstract][Full Text] [Related]
20. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
Varin R; Mirshahi S; Mirshahi P; Klein C; Jamshedov J; Chidiac J; Perzborn E; Mirshahi M; Soria C; Soria J
Thromb Res; 2013 Mar; 131(3):e100-9. PubMed ID: 23313382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]